TGFB2 and cardiac hypertrophy: Consistently, B38-CAP treatment significantly downregulated increased expression of mRNA associated with the pathology of cardiac hypertrophy (BNP and β-myhc) and fibrosis (Col8a1, Postn, and Tgfb2) (Fig. 7m–q).